AMLX

#1890
Amylyx Pharmaceuticals, Inc. Common Stock
15.17
+1.68%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
15.17
15.17
Intervallo Annuale
2.60
17.49
Variazione giornaliera
+1.68%
Variazione Mensile
-2.00%
Variazione di 6 mesi
+60.53%
Variazione Annuale
+384.66%
Chiusura Precedente
14.92
Open
15.17
Bid
Ask
Low
15.17
High
15.17
Volume
174
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
Income statement Balance sheet Cash flow
Value 202220232024

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Notizie